5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based TherapyLee M.G.a, d · Lee S.H.a, b · Lee S.J.a, c · Lee Y.S.a, c · Hwang J.-H.a, c · Ryu J.K.a, b · Kim Y.-T.a, b · Kim D.U.e · Woo S.M.f
aDepartments of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine and bDepartments of Internal Medicine, Seoul National University Hospital, Seoul, cDepartments of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, dDepartment of Internal Medicine, Hanmaeum Hospital, Jeju, eDepartment of Internal Medicine, Pusan National University School of Medicine, Busan, fCenter for Liver Cancer, National Cancer Center, Goyang, Korea
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background/Aims: There is no standard consensus on a strategy in the second-line setting for gemcitabine-refractory advanced pancreatic cancer. This study evaluated the activity and tolerability of oxaliplatin, irinotecan, 5-fluorouracil and leucovorin (FOLFIRINOX) as a second-line therapy in advanced pancreatic adenocarcinoma pretreated with a gemcitabine-based regimen. Methods: A retrospective survey was carried out on 18 patients with advanced pancreatic cancer who had been on gemcitabine-based chemotherapy and were then treated with FOLFIRINOX as a second-line therapy. Results: One patient (5.6%) had a confirmed complete response, 4 (22.2%) had confirmed partial responses and 5 (27.8%) had stable disease, resulting in a rate of disease control of 55.6% (95% CI, 33.3-77.8%). The median progression-free survival and median survival were 2.8 months and 8.4 months, respectively. Seven patients (38.9%) experienced grade 3-4 neutropenia. Grade 3 or 4 nonhematologic adverse events included nausea (38.9%) and vomiting (16.7%). Conclusions: These results suggest the modest clinical activity regarding efficacy and the acceptable toxicity profile with the FOLFIRINOX regimen as a second-line treatment.
© 2014 S. Karger AG, Basel
- Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
- Vincent A, Herman J, Schulick R, et al: Pancreatic cancer. Lancet 2011;378:607-620.
- Heinemann V: Present and future treatment of pancreatic cancer. Semin Oncol 2002;29:23-31.
- Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as a first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
- Haller DG: Future directions in the treatment of pancreatic cancer. Semin Oncol 2002;29:31-39.
- Maeda S, Motoi F, Onogawa T, et al: Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int J Clin Oncol 2011;16:539-545.
- Katopodis O, Polyzos A, Kentepozidis N, et al: Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother Pharmacol 2011;67:361-368.
- Cereda S, Reni M, Rognone A, et al: Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial. Chemotherapy 2011;57:156-161.
Pelzer U, Kubica K, Stieler J, et al: A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008;26:4508.
- Xiong HQ, Varadhachary GR, Blais JC, et al: Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008;113:2046-2052.
- Gebbia V, Maiello E, Giuliani F, et al: Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol 2007;18:vi124-vi127.
- Gebbia V, Maiello E, Giuliani F, et al: Irinotecan plus bolus/infusional 5-fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol 2010;33:461.
- Tempero MA, Arnoletti JP, Behrman SW, et al: Pancreatic Adenocarcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:703-713.
- Dahan L, Bonnetain F, Ychou M, et al: Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010;59:1527-1534.
- Boeck S, Heinemann V: The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncol 2008;4:41-50.
- Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New Engl J Med 2011;364:1817-1825.
- Assaf E, Verlinde-Carvalho M, Delbaldo C, et al: 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 2011;80:301-306.
- Lorgis V, Chauffert B, Gentil J, Ghiringhelli F: Influence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. Anticancer Res 2012;32:4125-4130.
- Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
DTCD NCID: Common Terminology Criteria for Adverse Events v3. 0 (CTAE). Cancer Therapy Evaluation Program 2006.
- Aapro MS, Cameron DA, Pettengell R, et al: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433.
- Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205.
- Pliarchopoulou K, Pectasides D: Pancreatic cancer: current and future treatment strategies. Cancer Treat Rev 2009;35:431-436.
- Saad ED, Machado MC, Wajsbrot D, et al: Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002;32:35-41.
- Maisey N, Norman A, Hill A, et al: CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 2005;93:740-743.
- Ishii H, Okada S, Sato T, et al: CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 1997;44:279.
- Reni M, Cereda S, Balzano G, et al: Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009;115:2630-2639.
Fogelman D, Pathak P, Qiao W, et al: Serum CA 19-9 level as a surrogate marker for prognosis in locally advanced pancreatic cancer (LAPC). J Clin Oncol 2008;26:15514.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.